Plasminogen Activators - Pipeline Insight, 2024

This “Plasminogen activators - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Plasminogen activators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Plasminogen activators Understanding

Plasminogen activators: Overview

Plasmin is the serine protease responsible for degradation of fibrin. Two forms of the zymogen precursor plasminogen circulate in plasma, the native more abundant form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by cleavage of the N-terminal peptide from Glu-plasminogen. The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. The first-generation plasminogen activators like streptokinase and urokinase are compounds found in nature that lack fibrin selectivity, while second-generation activators including t-PA and scu-PA are natural human proteins that possess some fibrin selectivity and can be produced either by selected human cell cultures or by recombinant DNA methods. The third-generation plasminogen activators are numerous compounds that are in clinical development and possess enhanced properties as a result either of chemical modification or of the application of recombinant DNA technology.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Plasminogen activators R&D. The therapies under development are focused on novel approaches for Plasminogen activators.

Plasminogen activators Emerging Drugs Chapters

This segment of the Plasminogen activators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plasminogen activators Emerging Drugs

TMS-007: TMSTMS-007 is a plasminogen activator based small molecule that is associated with breaking down blood clots, and is believed to inhibit local inflammation at the site of thrombosis. TMS-007 is designed to restore blood flow following acute stroke. TMS-007 is currently being evaluated in a Phase 2 study in Japan, in patients with acute ischemic stroke (AIS).

Recombinant staphylokinase: Supergene Recombinant staphylokinase is a Plasminogen activators containing Forteplase as the active substance. It is single chain molecule that consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism andstroke.

Plasminogen activators: Therapeutic Assessment

This segment of the report provides insights about the different Plasminogen activators drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Plasminogen activators

There are approx. 10+ key companies which are developing the Plasminogen activators. The companies which have their Plasminogen activators drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Plasminogen activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plasminogen activators: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Plasminogen activators therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plasminogen activators drugs.

Plasminogen activators Report Insights

• Plasminogen activators Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Plasminogen activators Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Plasminogen activators drugs?
• How many Plasminogen activators drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Plasminogen activators?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Plasminogen activators therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Plasminogen activators and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Genentech
• TMS
• Tasly Pharmaceutical
• Cereno Scientific
• Supergene
• Boehringer Ingelheim
• Chiesi Farmaceutici

Key Products

• Tenecteplase
• TMS 007
• Prourokinase recombinant
• CS-1
• Recombinant staphylokinase
• Alteplase
• CUSA-081

This product will be delivered within 2 business days.